GIP and GLP-1 receptor co-agonist
Tirzepatide 1 mg subcutaneous once weekly
TIRZ_SC_1MG_QW
Related
- All doses pooled: Tirzepatide injection
- Tirzepatide 5 mg subcutaneous once weekly
- Tirzepatide 10 mg subcutaneous once weekly
- Tirzepatide 15 mg subcutaneous once weekly
- Tirzepatide maximum tolerated dose injection once weekly
- Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg
- Tirzepatide 12 mg injection once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.95 (-1.34 to -0.55) | 0.51 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.02 (-2.11 to 2.16) | 0.19 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 2.98 (0.74 to 8.96) | 0.28 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.55 (0.01 to 40.74) | 0.45 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.59 (0.05 to 3.30) | 0.78 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -1.27 (-6.12 to 3.58) | 0.41 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 3.14 (0.64 to 14.82) | 0.43 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 1.69 (0.24 to 10.03) | 0.31 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.68 (0.11 to 2.59) | 0.62 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.46 (0.08 to 1.72) | 0.81 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.36 (0.07 to 1.19) | 0.89 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.65 (0.11 to 2.32) | 0.81 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.32 (0.53 to 2.96) | 0.58 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.74 (0.06 to 3.84) | 0.70 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.64 (0.04 to 7.53) | 0.53 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.68 (0.01 to 49.66) | 0.57 |